INTRODUCTION
Insulin-like growth factor I (IGF-I) is one of the putative mediators of the growth-promoting effects of growth hormone [1] . IGF-I has a structural similarity to insulin [2] , and its metabolic effects are considered to be similar to those of insulin [3] . Incubation of human or rat adipocytes with IGF-I increases the rates of glucose transport and glucose oxidation and inhibits that of lipolysis [4] [5] [6] [7] . Incubation of mouse soleus muscle, human muscle or rat diaphragm in vitro with IGF-I increases the rates of glucose phosphorylation [8, 9] , glycolysis and glycogen synthesis [3, 8, 10] , and intravenous administration of IGF-I lowers the blood glucose concentration in rats [3, 11] and in man [12] . However, in contrast with insulin, IGF-I is ineffective in suppressing hepatic glucose production, so that its hypoglycaemic effect after administration in vivo is presumably caused by an increase in the rate of glucose uptake in peripheral tissues [1 1,13,14] . Although skeletal muscle is considered to be the most important tissue for disposal of glucose [15] , there is little information on the effects of IGF-I and its interaction with insulin on glucose uptake and utilization in this tissue. This study was undertaken to examine the effects of IGF-I on the rates of glucose transport and glucose utilization in the isolated stripped soleus muscle incubated both in the absence and in the presence of various concentrations of insulin.
MATERIALS AND METHODS
Male Wistar rats of 140 g body wt. were used (Olac, Bicester, Oxon, U.K.). Rats were fasted for 12 h before each experiment, and they were killed by cervical dislocation. All chemicals, biochemicals, enzymes and radiolabelled substances were obtained from sources given previously [16, 17] .
Muscle incubations
Soleus muscle strips were prepared as previously described [16, 18] . The isolated muscles were transferred into siliconetreated 25 ml Erlenmeyer flasks with 3.5 ml of Krebs-Ringer bicarbonate buffer containing 1 mM-pyruvate, -succinate and -Lglutamate and 5.5 mM-D-glucose. Defatted BSA was added to a final concentration of 1.5 % (w/v) and the pH was adjusted to 7 .30. The medium was gassed with 02/CO2 (19: 1) during preparation and during the incubation, which was carried out at 37 'C. After 30 min, the muscles were transferred into other flasks containing 3.5 ml of identical Krebs-Ringer bicarbonate buffer except that pyruvate, succinate and L-glutamate were omitted but insulin was added (0-40 ng/ml). In each experiment, additional flasks which contained an identical amount of incubation buffer but no muscles were included as controls. After 60 min incubation, the muscles were quickly removed, blotted and freeze-clamped in liquid N2, and the frozen muscles were processed for determination of metabolites. The size of the muscle strips used in the experiments was 32+0.27 mg.
In the experiments where the effects of IGF-I were studied, IGF-I was added to the incubation medium at a final concentration of 25-30 ng/ml (3-3.6 nM). In the experiments in which the rate of 3-O-methylglucose transport was measured, IGF-I was also added to the preincubation medium at the same final concentration.
Glycolysis, glycogen synthesis and glucose oxidation For experiments in which the rates of glycogen synthesis and The rate of glucose transport was measured by using 3-0-methyl[3H]glucose, a glucose analogue which is transported but not further metabolized [23] . Muscles were incubated in KrebsRinger bicarbonate buffer identical with that described above, except that D-glucose was omitted. After 30 min preincubation, the muscles were further incubated for 10 min in buffer containing 3-O-methylglucose (5.5 mM), 3-O-methyl[3H]glucose and [U-_4C]sucrose (final specific radioactivities were 2 ,tCi/ml and 0.1 4tCi/ml respectively) and insulin. After incubation, the muscles were removed, washed briefly in ice-cold Krebs-Ringer bicarbonate buffer, blotted dry and freeze-clamped in liquid N2.
The frozen muscles were digested in 0.5 ml of 1 M-KOH at 70°C for 20-30 min. The muscle digest was transferred into scintillation vials and the tubes were rinsed once with 0.5 ml of distilled water. Scintillation fluid (10 ml) was added to the vials, the mixture was acidified with 150,l of acetic acid and the radioactivity was measured in a liquid-scintillation counter.
The net uptake of 2-deoxy[3H]glucose and 3-0-methyl-[3H]glucose into the muscles was calculated after correction for the 3H radioactivity trapped in the extracellular space; the latter was measured by using [14C]sucrose. Preliminary experiments established that the rate of 3-0-methyl[3H]glucose transport was linear for at least 20 min in the presence of 0.04 or 400 ng of insulin/ml.
The contents of glucose 6-phosphate [24] , fructose 1,6-bisphosphate [25], fructose 2,6-bisphosphate [26, 27] , ATP [28] , ADP [29] , AMP [29] , phosphocreatine [30] and citrate [31] were measured after extraction of the muscles with 6 % HC104.
The significance of the difference between controls and experimental results was tested by non-paired Student's t test.
RESULTS
Effects of IGF-I on the rates of glucose transport and utilization and the contents of glucose 6-phosphate and fructose 2,6-bisphosphate IGF-I increased the rate of 3-0-methylglucose transport, the flux of glucose to hexose monophosphate (representing the rate of total glucose utilization in the muscle) and the rates of lactate formation and glycogen synthesis. IGF-I had no significant effect on the rate of glucose oxidation; in contrast, insulin increased Table 2 . Effects of IGF-I (30 ng/ml) on the rates of 3-O-methylj3HJglucose transport, lactate formation, glycogen synthesis and flux of glucose to hexose monophosphate in the stripped soleus muscle of the rat at various concentrations of insulin Results are presented as means +S.E.M. of at least six separate incubations. Statistical significance was tested, and differences from controls are indicated by a p < 0.02, b p <'0.001; differences from values at basal concentrations of insulin (0-0.4 ng/ml) are indicated by t P < 0.02, * P < 0.01, ** P < 0.001.
[Insulin] (ng/ml) Table 3 . Effects of IGF-I (30 ng/ml) on the rate of phosphorylation and content of 2-deoxyl3Hjglucose in the stripped soleus muscle of the rat at various concentrations of insulin
Results are presented as means+ S.E.M. of at least six separate incubations. Statistical significance was tested, and differences from controls are indicated by a P < 0.02, b p < 0.001; differences from basal concentrations of insulin (0-0.4 ng/ml) are indicated by * P < 0.01 and ** P < 0.001. Table 2 ).
The rates of total lactate formation and ['4C]lactate formation increased similarly in response to IGF-I, but the basal rate of total lactate formation was higher than that of [14C]lactate formation. This difference was presumably caused by glycogenolysis and was similar in the absence (2.53 + 0.5 ,umol/h per g) or presence of IGF-I (3.00 + 0.38,tmol/h per g at 3000 ng/ml). This suggests that IGF-I, at the concentrations used, has no effect on the rate of glycogenolysis.
The rates of glucose transport and glucose utilization were similar at basal concentrations of IGF-I and insulin. However, maximal concentrations of IGF-I increased the flux of glucose to hexose monophosphate and the rates of 3-O-methylglucose transport and lactate formation to a greater extent than did the maximal concentrations of insulin (P < 0.02), whereas the effects on the rate of glycogen synthesis were not significantly different (Tables 1 and 2 ).
When the level of IGF-I was increased to 30 ng/ml, the rate of glucose transport, the flux of glucose to hexose monophosphate, the flux to glycogen and the glycolytic flux were increased; however, there was no significant increase in the content of glucose 6-phosphate, whereas that of fructose 2,6-bisphosphate increased by 600%. A further increase in the concentration of IGF-I to 300 or 3000 ng/ml further increased the rate of glucose transport, the flux of glucose to hexose monophosphate, the flux to glycogen and the glycolytic flux; in this case the content of glucose 6-phosphate doubled, but the content of fructose 2,6- bisphosphate increased by less than 400% (Table 1) .
Similarly, when the concentration of insulin was increased to 4 ng/ml, the rate of glucose transport, the flux to glycogen and the glycolytic flux were increased; however, the content of glucose 6-phosphate remained unaltered, but the content of fructose 2,6-bisphosphate increased by 40 %. An increase in the concentration of insulin to 40 ng/ml further increased the rate of glucose transport, the flux of glucose to glycogen and the glycolytic flux; in this case the content of glucose 6-phosphate increased by 1500%, whereas that of fructose 2,6-bisphosphate increased only slightly (16 %) (Tables 2 and 4) .
Calculation of the contribution of glycolysis and glycogen synthesis to glucose utilization showed that at 0 ng of IGF-I/ml the contribution to glycolysis was higher than that of glycogen synthesis (56+ 1.7% and 44+ 1.7% respectively; P < 0.001); at 3000 ng of IGF-I/ml the contributions of glycolysis and glycogen synthesis were similar (48 + 2 % and 52 + 2 % respectively).
Rates of glucose transport and utilization and contents of metabolites in muscle in response to IGF-I and insulin IGF-I at 25-30 ng/ml were used in these experiments to approximate to the physiological levels found in the plasma of fasting man [12] . At this concentration, IGF-I markedly increased the rates of lactate formation and glycogen synthesis and the flux Vol. 285 271 Table 4 . Effects of IGF-I (30 ng/ml) on the contents of glucose 6-phosphate, fructose 1,6-bisphosphate and fructose 2,6-bisphosphate in rat soleus muscle at various concentrations of insulin Results are presented as means + S.E.M. of at least four separate incubations. Statistical analysis was tested, and differences between controls and IGF-I are indicated by ap < 0.05, b p < 0.02, cP < 0.01 and dp < 0.001; differences from basal concentrations of insulin (0.04-0.4ng/ml) are indicated by * P < 0.05, ** P < 0.01; differences from values at 4 ng of insulin/ml are indicated by t P < 0.001. of glucose to hexose monophosphate at 0-4 ng of insulin/ml, but not at 40 ng of insulin/ml. However, the flux of glucose to hexose monophosphate and the rate of glycogen synthesis did not reach their maximal values: these rates were further increased as insulin increased from 0 to 4 ng/ml. In contrast, the rate of lactate formation did not increase further, even when insulin was added at maximal concentrations (Table 2) .
IGF-I increased the rates of 3-0-methylglucose transport and 2-deoxyglucose phosphorylation at 0-4 ng of insulin/ml, but not at 40 ng of insulin/ml. The rate of 3-0-methylglucose transport was increased maximally by IGF-I (Table 2) , whereas the rate of 2-deoxyglucose phosphorylation was further increased with increasing concentrations of insulin (Table 3) .
The content of 2-deoxyglucose increased as the level of insulin increased from basal to maximal. IGF-I increased the content of 2-deoxyglucose at 0-0.4 ng of insulin/ml, and in the presence of IGF-I increasing concentrations of insulin did not affect the content of 2-deoxyglucose (Table 3) . IGF-I decreased the content of glucose 6-phosphate and increased that of fructose 1,6-bisphosphate; also, IGF-I increased the content of fructose 2,6-bisphosphate at 0.4 and 4 ng of insulin/ml (Table 4 ). In the presence of IGF-I, the content of fructose 1,6-bisphosphate at 0 ng of insulin/ml was higher than that observed at 40 ng of insulin/ml (Table 4) .
IGF-I, either alone or in combination with insulin, had no effect on the contents of ATP, ADP, AMP, phosphocreatine or citrate (Table 5) .
DISCUSSION
The results suggest that IGF-I can stimulate the rate of glucose utilization in muscle independently of insulin. Furthermore, IGF-I can increase the rate of conversion of glucose into lactate. To identify the mechanism(s) by which IGF-I stimulates glucose utilization, the rates of glucose transport, glycolysis and glycogen synthesis and the contents of some glycolytic intermediates and effectors were measured in the incubated muscle.
The IGF-I dose-response experiments presented in Table 1 suggest that the increase in the rate of glycolysis is caused, in part, by a stimulation of glucose transport. The finding that the increase in the rate of 3-0-methylglucose transport caused by a sub-maximal, near-physiological, concentration of IGF-I (30 ng/ml) was similar to that produced by a maximal concentration ofinsulin suggests that IGF-I results in a redistribution of glucose transporters from the intracellular pool to the plasma membrane. This mechanism has been established for insulin in skeletal muscle [32, 33] . This suggestion is supported by the finding that IGF-I did not have an additive effect with insulin on the rate of 3-0-methylglucose transport. However, the observation that a maximal concentration of IGF-I increased the rate of 3-0-methylglucose transport to a greater extent than did a maximal concentration of insulin suggests that IGF-I either also increased the activity of those transporters already in the membrane or caused a net increase in translocation of other transporters (e.g. glut-I) to the plasma membrane. The physiological importance of the effect of IGF-I on glucose transport is that it may be the main mechanism by which IGF-I produces a hypoglycaemic effect in vivo, since it does not affect hepatic glucose production, nor does it decrease the rate of fatty acid mobilization from adipose tissue [11, 13, 14] .
The increase in the rate of glucose transport may not be the only mechanism by which IGF-I increases the rate of glycolysis and lactate formation, but this peptide may have additional effects that facilitate the glycolytic process. The changes in the content of glucose 6-phosphate suggest that IGF-I may increase the activity of 6-phosphofructokinase by a mechanism independent of fructose 6-phosphate. Thus, when IGF-I was increased from 0 to 30 ng/ml, the flux through this enzyme was increased (since the rate of glycolysis was increased), yet the content of glucose 6-phosphate, and presumably that of fructose 6-phosphate, with which it is in equilibrium, remained unaltered; this suggests that IGF-I must have enhanced the activity of a reaction further down the glycolytic pathway, which is likely to be 6-phosphofructokinase. The increase in the rate of glycolysis caused by IGF-I (in combination with the increase in the rate of glycogen synthesis) may, when insulin is also present, decrease the content of glucose 6-phosphate; the latter effect would be expected to increase the activity of hexokinase, since glucose 6- phosphate is a potent inhibitor of hexokinase [32] ; this could contribute to the increase in the rate of glucose phosphorylation. These results support the suggestion that IGF-I, by increasing the activity of 6-phosphofructokinase, and hence that of hexokinase, should facilitate the increase in the glycolytic rate caused by the increase in the rate of glucose transport.
IGF-I increased the rate of glycogen synthesis. In mouse soleus muscle, IGF-I has been reported to increase the activity of glycogen synthase [8] . However, the stimulation of glucose transport cannot explain the effect of IGF-I on glycogen synthesis: the enzyme glycogen synthase is considered to catalyse a flux-generating step, so that it will not be influenced by a change in the concentration of its substrate, UDP-glucose. Furthermore, IGF-I decreased the concentration of glucose 6-phosphate, a known activator of this enzyme [32] .
In the present study, a maximally effective insulin concentration increased the rate of glucose utilization; this effect was smaller than that observed in vivo when infusions of labelled glucose are used [34] . However, in vivo, these effects of insulin could be facilitated by some indirect effects of this hormone, such as decreasing the plasma level of alternative fuels (fatty acids, ketone bodies) which are known to influence the activity of 6-phosphofructokinase and hence hexokinase [32] . The soleusmuscle preparation provides an isolated system in which the effects of insulin can be studied with minimal influence by other factors.
The mechanism by which IGF-I increases the activity of 6-phosphofructokinase could be via stimulation by fructose 2,6-bisphosphate, since in the presence of IGF-I the content of fructose 2,6-bisphosphate was increased, whereas the contents of other effectors of this enzyme were not affected. Fructose 2,6-bisphosphate is a potent activator of 6-phosphofructokinase, but its role in the regulation of glucose utilization in skeletal muscle has not been established. Since fructose 2,6-bisphosphate is neither a substrate nor an intermediate of glycolysis, it would be an apt mediator for extracellular signals such as hormones [27, 35] . In the present experiments, the changes in the content of fructose 2,6-bisphosphate in muscle in response to IGF-I or insulin coincide with those observed in the glycolytic rate, but are opposite to the changes observed in the content of glucose 6- phosphate. This suggests that, when IGF-I is increased within the range 0-30 ng/ml, an increase in fructose 2,6-bisphosphate is part of the mechanism to increase the activity of 6-phosphofructokinase and hence the glycolytic flux; this, along with a simultaneous direct effect of IGF-I to increase the rate of glycogen synthesis, would maintain the content of glucose 6-phosphate unaltered, although the rate of glucose transport is increased. Similar suggestions can be made when the level of insulin is increased within the physiological range (Table 4) . In contrast, the increase in glucose 6-phosphate at supraphysiological levels of insulin may be caused by a further increase in the rate of glucose transport not matched with a stimulation of 6-phosphofructokinase activity; in this case, the increase in 6-phosphofructokinase and the stimulation of glycolysis could be caused solely by an increase in the content of intracellular glucose consequent upon stimulation of glucose transport; indeed, the content of 2-deoxyglucose in the soleus muscle was increased when insulin increased from physiological to maximal levels. At these supraphysiological concentrations of insulin, this would also help to direct glucose residues to glycogen rather than to lactate [34] . Similarly, when the level of IGF-I increased from 30 to 3000 ng/ml, the content of glucose 6-phosphate doubled; this latter increase may be explained, at least in part, by the lower increases in the content of fructose 2,6-bisphosphate and the rate of glycolysis compared with those produced at concentrations of IGF-I below 30 ng/ml. These results suggest that changes in the content of fructose 2,6-bisphosphate may play an important role in the regulation of glucose fluxes in skeletal muscle in response to either IGF-I or insulin. In a recent study in working frog muscle, changes in glycolytic flux were closely correlated with changes in the content of fructose 2,6-bisphosphate [27] .
Near-physiological concentrations of IGF-I not only decreased the content of glucose 6-phosphate, but also increased that of fructose 1,6-bisphosphate: such a 'cross-over effect' is consistent with an increase in the activity of 6-phosphofructokinase. However, a comparison of the effects of IGF-I alone (at 30 ng/ml) with insulin alone (at 40 ng/ml) reveals that, despite a similar glycolytic flux and fructose 2,6-bisphosphate content, the content of fructose 1,6-bisphosphate was increased in the presence of IGF-I. This raises the possibility that insulin may result in an increase in the activity of one or more enzymes below 6-phosphofructokinase (e.g. glyceraldehyde-phosphate dehydrogenase via small change in the redox state).
Despite the similarities between effects of IGF-I and insulin on glucose metabolism, the effects of IGF-I are considered to occur via the IGF-I receptor and not the insulin receptor [8, [36] [37] [38] . This is further supported by the finding that IGF-I seems to have a preferential effect on the rate of glycolysis and lactate formation.
In summary, IGF-I increases the rate of glucose transport in the isolated soleus muscle, but also affects the subsequent disposition of glucose: it increases the rates of glycolysis and glycogen synthesis, but not the rate of glucose oxidation. The increase in the rate of glycolysis and lactate formation in muscle by IGF-I might be expected to increase the activity of Cori cycle to a greater extent than insulin, and therefore provide substrate for the 'indirect' pathway of hepatic glycogen synthesis.
